This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Novartis (NVS) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.
Here's Why You Should Add ImmunoGen (IMGN) to Your Portfolio Now
by Zacks Equity Research
ImmunoGen's (IMGN) recently launched drug, Elahere, is expected to generate incremental revenues for the company and boost its top-line growth in the next few years.
AbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease
by Zacks Equity Research
AbbVie (ABBV) announces the seventh FDA approval of its JAK inhibitor, Rinvoq, for the treatment of adults with moderately to severely active Crohn's disease.
Bausch (BHC) Gains on Court Ruling for Xifaxan Against Norwich
by Zacks Equity Research
Bausch (BHC) obtains a positive ruling for one of its top drugs, Xifaxan, against Norwich from the U.S. District Court of Delaware. Stock up in response to the same.
Roche's (RHHBY) MS Drug Meets Goals in the Phase II Study
by Zacks Equity Research
Roche's (RHHBY) investigational oral fenebrutinib meets its primary and secondary endpoints in the phase II FENopta study.
Bayer's (BAYRY) Arrhythmia Prevention Drug Gets Fast Track Tag
by Zacks Equity Research
Bayer's (BAYRY) oral FXIa inhibitor, asundexian, gets the FDA's Fast Track Designation, as a preventive treatment for stroke and systemic embolism in people with atrial fibrillation.
Eli Lilly (LLY) Stock Up 18.7% YTD, New Drugs Key to Growth
by Zacks Equity Research
Lilly (LLY) expects to launch four new medicines by 2023 end, of which Mounjaro for type II diabetes and cancer drug Jaypirca have already been launched.
Bayer (BAYRY) Q1 Earnings Beat, Crop Science Sales Decline
by Zacks Equity Research
Bayer (BAYRY) tops on first-quarter 2023 earnings but misses on sales. Management reiterates guidance.
Biotech ETFs Pop on M&A Resurgence
by Neena Mishra
2023 could be a year of heightened biotech dealmaking activity
What Makes Novartis (NVS) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Novartis (NVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Novartis (NVS) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
Top Stock Reports for Eli Lilly, Verizon Communications & United Parcel Service
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Verizon Communications Inc. (VZ) and United Parcel Service, Inc. (UPS).
Here's Why Novartis (NVS) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks.com featured highlights include PulteGroup, Novartis, Boyd Gaming, Cummins and W.W. Grainger
by Zacks Equity Research
PulteGroup, Novartis, Boyd Gaming, Cummins and W.W. Grainger are part of the Zacks Screen of the Week article.
5 Dividend Growth Stocks to Buy for Safe Returns
by Sweta Killa
PulteGroup (PHM), Novartis (NVS), Boyd Gaming (BYD), Cummins (CMI) and W.W. Grainger (GWW) could be solid choices for your portfolio.
Alnylam (ALNY) Q1 Earnings Beat, Product Sales Drive Revenues
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) reports better-than-expected first-quarter 2023 results. Givlaari, Oxlumo and the newly approved Amvuttra drive revenues for the company.
Novartis (NVS) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.
Incyte (INCY) Q1 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Incyte's (INCY) first-quarter 2023 earnings and revenues miss estimates due to higher patient deductibles and inventory challenges.
AbbVie (ABBV) Q1 Earnings Beat, Skyrizi Sales Underperform
by Zacks Equity Research
AbbVie's (ABBV) first-quarter 2023 earnings and sales beat estimates. However, share price dives as some key drugs miss sales estimates.
Will Jakafi Sales Drive a Beat For Incyte (INCY) Q1 Earnings?
by Zacks Equity Research
Incyte's (INCY) first-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
Novartis (NVS) Tops on Q1 Earnings & Revenues, Ups View
by Zacks Equity Research
Novartis (NVS) beats on earnings and sales in the first quarter, and raises its annual guidance on strong momentum.
Novartis (NVS) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Incyte (INCY) Opzelura Gets EC Nod for Non-Segmental Vitiligo
by Zacks Equity Research
Incyte (INCY) gets EC approval for Opzelura (cream formulation of ruxolitinib) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
Are Medical Stocks Lagging Novo Nordisk (NVO) This Year?
by Zacks Equity Research
Here is how Novo Nordisk (NVO) and Novartis (NVS) have performed compared to their sector so far this year.
Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.